Login

Switch On Your HIV Smarts.

An “Improved Backbone” for New HIV Regimens Now Under FDA Review

An “Improved Backbone” for New HIV Regimens Now Under FDA Review

, by Emily Newman

A new version of tenofovir may result in a better-tolerated replacement for Truvada. Read More

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

, by Emily Newman

An integrase inhibitor fared well in a head-to-head comparison with a protease inhibitor regimen for people just starting ART. Find out why this is surprising and what it could mean for treatment naïve people with high viral loads. Read More

HIV and Cardiovascular Risk: Early Statin Use May Help

HIV and Cardiovascular Risk: Early Statin Use May Help

, by Emily Newman

Cholesterol-lowering drugs may help people with HIV mitigate heightened risk of heart trouble. Read More

Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start

Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start

, by Emily Newman

Gains in abdominal body fat and other types of lipodystrophy can be one side effect of antiretroviral therapy. New research gives insight into one potential cause. Read More

CROI 2015: Tenofovir Alafenamide and a New Maturation Inhibitor

CROI 2015: Tenofovir Alafenamide and a New Maturation Inhibitor

, by Liz Highleyman

What’s new in the world of HIV drug development? CROI brought us updates on a potentially safer version of tenofovir and a new type of drug that just established proof-of-concept. Read More